Group 1 - The transaction involves the subsidiary Luzhou Buchang signing an exclusive supply agreement with Malaysian company MEDISPEC for the drug Efparepoetin alfa [1] - MEDISPEC will act as the exclusive agent in Malaysia, responsible for the registration, promotion, distribution, and sales of the product [1] - The agreement is valid for 10 years from the date of obtaining the import license, with a potential 5-year extension for good performance [1] Group 2 - The product, Efparepoetin alfa, is aimed at treating anemia in chronic kidney disease dialysis patients and is classified as a Class I new biological drug with no similar products approved in China [1] - The company has invested approximately 512 million yuan in research and development as of September 30, 2025 [1] - A listing application for the product has already been submitted [1] Group 3 - MEDISPEC is responsible for the product registration and will bear the associated costs, while Luzhou Buchang will provide technical support [1] - Intellectual property rights for the product remain with Luzhou Buchang [1] - The agreement is governed by Chinese law, with disputes to be submitted to the Hong Kong International Arbitration Centre [1]

山东步长制药股份有限公司 关于控股子公司泸州步长与 MEDISPEC 签署《独家供应协议》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、交易概述 在当前中国医药企业积极"走出去"的大背景下，为实现山东步长制药股份 有限公司（以下简称"公司"或"步长制药"）产品国际化战略，为公司带来更 好的经济效益，同时提升公司品牌的影响力，公司控股子公司四川泸州步长生物 制药有限公司（以下简称"泸州步长"）拟与马来西亚公司 MEDISPEC（M）SDN BHD（以下简称"MEDISPEC"）签署《独家供应协议》，泸州步长拟授权 证券代码：603858 证券简称：步长制药 公告编号：2025-241 交易简要内容：公司控股子公司泸州步长拟与马来西亚公司 MEDISPEC 签署《独家供应协议》，泸州步长拟授权 MEDISPEC 作为目标区域内独 家代理商，在目标区域内完成注射用 Efparepoetin alfa 的注册、推广、 分销及销售事宜。 根据业务要求，本次交易的交易金额及交易对方主要财务数据涉及商业 秘密， ...

山东步长制药股份有限公司 关于控股子公司涉及诉讼事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次诉讼的基本情况 山东步长制药股份有限公司（以下简称"公司"）控股子公司上海合璞医疗 科技有限公司（以下简称"上海合璞"）因合同纠纷向上海市第一中级人民法院 提交诉讼申请，法院受理并予以立案，于 2025 年 11 月 5 日出具了《受理案件通 知书》[案号：（2025）沪 01 民初 257 号]。具体情况如下： 证券代码：603858 证券简称：步长制药 公告编号：2025-242 案件所处的诉讼阶段：已立案受理，尚未开庭审理。 上市公司所处的当事人地位：公司控股子公司上海合璞为案件原告。 涉案的金额：人民币 651,889,371.82 元。 是否会对上市公司损益产生影响：本次诉讼事项法院已立案受理，尚未 开庭审理，案件的最终结果存在不确定性，涉及 5.5 亿元左右存货存在 计提存货跌价准备的风险，对公司本期利润及期后利润影响金额尚不能 确定。 原告：上海合璞医疗科技有限公司 被告：捷迈(上海 ...

Core Viewpoint - The company, Buchang Pharma, announced that its subsidiary, Luzhou Buchang, plans to sign an exclusive supply agreement with Malaysian company MEDISPEC for the registration, promotion, distribution, and sales of injectable Efparepoetin alfa in a designated region [1] Group 1 - Luzhou Buchang will authorize MEDISPEC as the exclusive agent in the target area for the product [1] - Injectable Efparepoetin alfa is a recombinant fusion protein composed of erythropoietin (EPO) and human immunoglobulin G2 (IgG2) Fc fragment [1] - There are currently no similar products approved for sale in the domestic market [1]

Core Viewpoint - A comprehensive green transformation is underway in Shandong, focusing on circular economy principles across various industries, driving high-quality regional economic development [1][11]. Group 1: Pharmaceutical Industry - The demand for traditional Chinese medicine and natural drugs is rising, leading to challenges in managing by-products like medicinal residues [1]. - Shandong Buchang Pharmaceutical Co., Ltd. invested over 50 million RMB in 2015 to establish a waste disposal and energy utilization center, achieving closed-loop management of medicinal waste [1]. - The company employs various technologies to eliminate odor emissions from the extraction process, ensuring compliance with environmental standards [3]. Group 2: Agricultural Waste Utilization - Shandong Yuncheng Qiquan Biomass Power Generation Co., Ltd. processes 600,000 tons of agricultural and forestry waste annually, generating 350 million kWh of electricity, which reduces coal consumption by 230,000 tons and CO2 emissions by 560,000 tons each year [4]. - The company has established a waste recovery network covering a 100-kilometer radius, creating a market with an annual output value exceeding 100 million RMB, benefiting local farmers [7]. Group 3: Chemical Industry - The Ningyang Chemical Industry Park has implemented a 7,000-meter public pipeline system for efficient transportation of industrial gases and liquids, saving over 100 million RMB in costs annually for participating companies [7]. - The park has developed eight chemical industry chains, with the "synthetic ammonia—nitric acid—nitrobenzene—rubber additives" chain generating over 3.5 billion RMB in output value [10]. Group 4: Renewable Energy and Waste Management - The use of retired wind turbine blades to create artificial reefs demonstrates innovative waste management, providing a cost-effective solution that enhances marine habitats [10]. - The company has developed the first domestic high-efficiency processing equipment for retired blades, enabling the recycling of materials for use in construction [10]. Group 5: Overall Economic Impact - The integration of technology and circular economy principles across various sectors is contributing to Shandong's economic transformation, emphasizing energy conservation, emission reduction, and increased value [11].

（编辑 丛可心 袁冠琳） 证券日报网讯 12月25日，步长制药在互动平台回答投资者提问时表示，子公司丹红制药与翼菲合作的 工业机器人已应用于生产环节，有效提升了生产效率与质量管控水平。公司高度关注人工智能等前沿技 术发展，相关布局将结合战略规划稳步推进，敬请关注公司公告。 ...

Core Viewpoint - The company has established its export presence in the European market over the past two years, primarily through partnerships in the Eurasian Economic Union countries [1] Group 1: Market Expansion - In 2024, the company's subsidiary, Luzhou Buchang, will sign an agreement with Russia's LANCET company to authorize the registration and commercialization of injectable BC001 in the region [1] - The company has successfully sold multiple traditional Chinese medicine products to dozens of countries and regions worldwide [1] Group 2: Regulatory Progress - The company is currently advancing the EU COS certification for its main products in core EU countries, with future sales progress to be monitored through special responses and related announcements [1]

证券日报网讯 12月24日，步长制药发布公告称，公司第五届董事会第三十九次会议审议通过《关于山 东步长众鑫康医药科技有限公司拟对外投资的议案》等。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Buchang Pharma announced a board meeting to discuss an investment proposal related to Shandong Buchang Zhongxin Kang Pharmaceutical Technology Co., indicating ongoing strategic initiatives within the company [1] - For the year 2024, Buchang Pharma's revenue composition is heavily weighted towards the pharmaceutical industry, accounting for 99.71%, while other business segments contribute only 0.29% [1] - As of the report, Buchang Pharma's market capitalization stands at 17.4 billion yuan [1]

格隆汇12月24日丨步长制药(603858.SH)公布，为丰富山东步长制药股份有限公司产品研发管线，公司 全资子公司山东丹红制药有限公司（简称"山东丹红"）拟与陕西功能食品工程中心有限公司（简称"陕 西功能食品工程中心"）就云亭牌阿胶地黄口服液、悦心牌葡萄籽维生素E软胶囊、同健牌芦荟荷叶软 胶囊、秦歧牌丹参当归胶囊、云亭牌钙锌口服液、正生源?维生素E软胶囊（成人）6个保健食品（简 称"6个保健食品"）技术转让事宜签署《技术转让合同》。"6个保健食品"为已获批文的保健食品，其相 关批件及所有权分属其他6家不同的独立法人主体。陕西功能食品工程中心协调、促使6家标的权属方将 其拥有的6个保健食品的技术所有权以750万元人民币的价格转让予山东丹红，双方依据合同中所约定的 责任和义务，遵循《保健食品注册与备案管理办法》《保健食品注册申请服务指南（2016年版）》及相 关法规要求，开展6个保健食品的技术转让/备案工作，最终确保山东丹红获得该6个保健食品的保健食 品注册证书/备案凭证，并实现商业化规模生产。 ...